AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1. (pnas.org)

Authors: Li X … Yuan F Journal: PNAS Published: 2026-05-05 DOI: https://doi.org/10.1073/pnas.2534978123